(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 June 2011 (03.06.2011)

PCT

(10) International Publication Number
WO 2011/063980 A1

(51) International Patent Classification:
C07K 16/18 (2006.01)

(21) International Application Number:
PCT/EP2010/007197

(22) International Filing Date:
26 November 2010 (26.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09014745.5 26 November 2009 (26.11.2009) EP
61/264,696 26 November 2009 (26.11.2009) US

(71) Applicant *(for all designated States except US)*: **INFLARX GMBH** [—/DE]; Winzerlaer Str. 2, 07745 Jena (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GUO, Renfeng** [CN/US]; 5816 Villa France Ave, Ann Arbor, MI 48103 (US). **RIEDEMANN, Niels, Christoph** [DE/DE]; Fröbelstieg 8, 07743 Jena (DE). **LI, Yan** [CN/CN]; Beijing Mabworks Biotech Co., Ltd., Building No.3, Huilongsen Science Park, 14 Kechuang Street, 1 Jinghai Road, Ciqu Town, Tongzhou District, Beijing (CN). **SHEN, Beifen** [CN/CN]; Beijing Mabworks Biotech Co., Ltd., Building No.3, Huilongsen Science Park, 14 Kechuang Street, 1 Jinghai Road, Ciqu Town, Tongzhou District, Beijing (CN).

(74) Agents: **VOSSIUS, Volker** et al.; Geibelstrasse 6, 81679 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

[Continued on next page]

(54) **Title**: ANTI-C5A BINDING MOIETIES WITH HIGH BLOCKING ACTIVITY

Fig. 1



(57) **Abstract**: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.

WO 2011/063980 A1

— *with sequence listing part of description (Rule 5.2(a))*